Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 6Breast 6Tumor-Agnostic 4Sarcoma 4Other hematologic neoplasm 3Gynecologic 3Genitourinary 2Dermatologic 2Plasma cell 1Other solid neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1

Conditions

Myeloproliferative Disorders 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 259fludarabine phosphate 232Azacitidine 180fludarabine 179Busulfan 174Cytarabine 154Mycophenolic Acid 147Tacrolimus 145Whole-Body Irradiation 141Imatinib Mesylate 141Peripheral Blood Stem Cell Transplantation 139Cyclosporine 110Antilymphocyte Serum 108Melphalan 106Methotrexate 105Filgrastim 101Decitabine 98nilotinib 82venetoclax 77ruxolitinib 72Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 62Dasatinib 62Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × STA 9090 × Myeloid × Clear all
NCT00858572 2014-09-18

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

Synta Pharmaceuticals Corp.

Phase 1 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡